Blue Ridge Capital’s MacroGenics MGNX Stock Holding History

Blue Ridge Capital’s Portfolio MGNX Stock Details MGNX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-1,360,000	Closed	-$25.3M	–	43
2017 Q1	$25.3M	Hold	1,360,000	–	–	0.33%	40
2016 Q4	$27.8M	Hold	1,360,000	–	–	0.35%	46
2016 Q3	$40.7M	Hold	1,360,000	–	–	0.48%	45
2016 Q2	$36.7M	Hold	1,360,000	–	–	0.47%	44
2016 Q1	$25.5M	Buy	1,360,000 +10,000	+0.7%	+$190K	0.31%	47
2015 Q4	$41.8M	Hold	1,350,000	–	–	0.47%	40
2015 Q3	$28.9M	Hold	1,350,000	–	–	0.33%	46
2015 Q2	$51.3M	Hold	1,350,000	–	–	0.58%	43
2015 Q1	$42.4M	Hold	1,350,000	–	–	0.48%	41
2014 Q4	$47.3M	Hold	1,350,000	–	–	0.57%	41
2014 Q3	$28.2M	Buy	1,350,000 +450,000	+50%	+$9.31M	0.33%	41
2014 Q2	$19.6K	Hold	900,000	–	–	0.19%	45
2014 Q1	$25M	Hold	900,000	–	–	0.28%	44
2013 Q4	$24.7M	Buy	+900,000	New	+$23.5M	0.25%	48

Other funds holding MGNX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

IVM

InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Blue Ridge Capital's MGNX Position: Q2 2017 in Review

Blue Ridge Capital sold out of MacroGenics (MGNX) in Q2 2017, closing a stake of 1,360,000 shares — an estimated $25.3M sold.

Blue Ridge Capital first reported a position in MGNX in Q4 2013 and held it in 14 quarters. The position peaked at $51.3M in Q2 2015. 113 funds tracked by Wall St. Rank hold MGNX as of Q2 2017.

Blue Ridge Capital reported no remaining MacroGenics position as of Q2 2017 after selling out during the quarter.
Blue Ridge Capital sold 1,360,000 MacroGenics shares in Q2 2017, an estimated $25.3M.
Blue Ridge Capital first reported a position in MacroGenics in Q4 2013 and held it in 14 quarters.
Blue Ridge Capital's MacroGenics position peaked at $51.3M in Q2 2015.
113 funds tracked by Wall St. Rank held MacroGenics as of Q2 2017.

Based on Blue Ridge Capital's 13F filing for Q2 2017, filed 14 Aug 2017.